Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
40.2M
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
6.5M
-
Shares change
-
-370K
-
Total reported value, excl. options
-
$33.2M
-
Value change
-
-$1.96M
-
Number of buys
-
11
-
Number of sells
-
-19
-
Price
-
$5.11
Significant Holders of Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share (TARA) as of Q1 2022
37 filings reported holding TARA - Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2022.
Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share (TARA) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.5M shares
of 40.2M outstanding shares and own 16.14% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.67M shares), ORBIMED ADVISORS LLC (831K shares), VANGUARD GROUP INC (427K shares), CITADEL ADVISORS LLC (406K shares), PERCEPTIVE ADVISORS LLC (384K shares), Ikarian Capital, LLC (296K shares), DLD Asset Management, LP (230K shares), BOXER CAPITAL, LLC (209K shares), BAKER BROS. ADVISORS LP (200K shares), and GOLDMAN SACHS GROUP INC (153K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.